Targets › PSMA
31 programs from 27 companies in 42 trials: 25 Phase 1, 12 Phase 2, 4 Phase 3, 1 Phase 4; Oncology; next expected readout Dec 2026.
Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. (UniProt, Q04609)
Open in Phaseline: the race on PSMA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Lantheus Medical Imaging | Piflufolastat F 18 Prostate-specific membrane antigen (PSMA)-targeting PET imaging agent | PSMA | Phase 4 | Prostate Cancer | – |
| Clarity Pharmaceuticals | 64Cu-SAR-bisPSMA 64Cu-labeled anti-PSMA bisPSMA antibody for imaging | PSMA, FOLH1 | Phase 3 | Prostate Cancer; Prostatic Neoplasms, Castration-Resistant | Dec 2026 |
| POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | [Lu-177]-PNT2002 Lutetium-177 labeled PSMA targeted radioligand therapy | PSMA | Phase 3 | Metastatic Castration-Resistant Prostate Cancer | Mar 2028 |
| Curium US | 177Lu-PSMA-I&T Lutetium-177 labeled PSMA-targeting radioligand therapy | PSMA | Phase 3 | Metastasis From Malignant Tumor of Prostate; Prostate Cancer | Feb 2029 |
| Fusion Pharmaceuticals | FPI-2265 Ac-225-labeled PSMA-targeting small molecule (targeted alpha therapy) | PSMA, FOLH1 | Phase 2 | Metastatic Castration Resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer | Dec 2026 |
| Peter MacCallum Cancer Centre, Australia | 177Lu-PSMA PSMA-targeting radiopharmaceutical (lutetium-177 beta emitter) | PSMA | Phase 2 | Oligometastatic Prostate Cancer | May 2027 |
| Weill Medical College of Cornell University | 177Lu-J591 PSMA-targeted radioimmunotherapy; humanized monoclonal antibody against prostate-specific | PSMA | Phase 2 | Prostate Cancer | Jun 2027 |
| First Affiliated Hospital of Fujian Medical University | 177Lu-P17-088 PSMA-targeted radioligand (lutetium-177 conjugate with albumin-binding property) | PSMA | Phase 2 | Prostate Cancer | Jun 2027 |
| National Cancer Institute (NCI) | 18F-DCFPyL High affinity small molecule inhibitor of PSMA for PET imaging | PSMA | Phase 2 | Prostate Cancer; Metastatic Prostate Cancer; Localized Prostate Cancer; Prostatic Neoplasms … | Nov 2027 |
| Columbia University | [18F]DCFPyL PSMA-targeting PET imaging agent | PSMA | Phase 2 | Metastatic Prostate Cancer | – |
| Weill Medical College of Cornell University | 225Ac-J591 Alpha-emitter radiopharmaceutical; Actinium-225 conjugated to anti-PSMA antibody J591 | PSMA, FOLH1 | Phase 1 | Prostate Cancer | Dec 2026 |
| Jonsson Comprehensive Cancer Center | 177Lu-PSMA Lutetium-177 labeled PSMA-targeting radioligand | PSMA | Phase 1 | Castration-Resistant Prostate Carcinoma | Dec 2026 |
| C Ray Therapeutics | TRDC002 PSMA-targeting radiotracer (64Cu-labeled) | PSMA | Phase 1 | Prostate Cancer | Dec 2026 |
| Xiaorong Sun | [225Ac]Ac-PSMA-XT Alpha-emitting radiopharmaceutical targeting PSMA | PSMA | Phase 1 | Metastatic Castration-Resistant Prostate Cancer Patients | Dec 2026 |
| M.D. Anderson Cancer Center | Piflufolastat F18 PSMA-targeted PET imaging agent | PSMA | Phase 1 | Pancreatic Cancer | Feb 2027 |
| Beijing Biotech | ETB-DualNK-01 Dual-target anti-PSMA/PSCA CAR-NK cells | PSMA, PSCA | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Mar 2027 |
| Jinming Zhang | [177Lu]Lu-PSMA-XT Radioligand therapy delivering beta-particle radiation to PSMA-expressing cells | PSMA | Phase 1 | mCRPC | Apr 2027 |
| Chunjing Yu | Lu 177-PSMA-3D1015 Injection PSMA-targeted radioligand therapy (lutetium-177 labeled) | PSMA | Phase 1 | Metastatic Castration-resistant Prostate Cancer, mCRPC | Jun 2027 |
| Eli Lilly | [Ac-225]-PSMA-62 Actinium-225 labeled anti-PSMA targeted alpha particle therapy | PSMA | Phase 1 | Prostate Cancer | Sep 2027 |
| ARTBIO | AB001 Pb-212 PSMA-targeted alpha-emitting radioligand | PSMA | Phase 1 | Prostate Cancer (CRPC) | Nov 2027 |
| C Ray Therapeutics | TRC003 225Ac-labeled PSMA-targeted alpha particle therapy (targeted alpha therapy) | PSMA | Phase 1 | Prostate Cancer | Dec 2027 |
| Inovio Pharmaceuticals | INO-5401 DNA plasmid encoding WT1, PSMA, and hTERT tumor-associated antigens | WT1, PSMA, HGNC | Phase 1 | Glioblastoma | Dec 2027 |
| Blue Earth Therapeutics | Lutetium (177Lu) rhPSMA-10.1 Injection 177Lu-labeled recombinant human PSMA-targeting radiopharmaceutical | PSMA | Phase 1 | Prostate Cancer | Mar 2028 |
| University Hospital, Basel, Switzerland | 161Tb-SibuDAB PSMA-targeted radionuclide therapy with terbium-161 | PSMA | Phase 1 | Castration-resistant Prostate Cancer | Jun 2028 |
| Peter MacCallum Cancer Centre, Australia | [161Tb]Tb-PSMA-I&T Prostate-specific membrane antigen (PSMA) targeted radioligand therapy using terbium-161 | PSMA | Phase 1 | Prostate Cancer | Sep 2028 |
| Bayer | 225Ac-PSMA-Trillium (BAY3563254) PSMA-targeting alpha-emitting radioligand (actinium-225) | PSMA | Phase 1 | Advanced Metastatic Castration-resistant Prostate Cancer | Nov 2028 |
| Yunhe Pharmaceutical (Tianjin) Co., Ltd | INR102 injection Lutetium-177-labeled radiopharmaceutical targeting PSMA | PSMA | Phase 1 | Prostate Cancer | Jun 2029 |
| Norroy Bioscience | 177Lu-NYM032 injection PSMA-targeting radioligand therapeutic agent | PSMA | Phase 1 | Metastatic Castration-resistant Prostate Cancer | – |
| Clarity Pharmaceuticals | 67Cu-SAR-bisPSMA 67Cu-labeled anti-PSMA bisPSMA antibody for therapeutic targeting | PSMA | Phase 1 | Prostatic Neoplasms, Castration-Resistant | – |
| Nova Therapeutics | CART-PSMA cells CAR-T cell therapy targeting PSMA (prostate-specific membrane antigen) | PSMA | Phase 1 | Prostate Cancer | – |
| Sinotau Pharmaceutical Group | Flotufolastat F-18 Injection PSMA-targeted PET imaging tracer | PSMA | Phase 1 | Prostate Cancer | – |
Prostate Cancer (18) Metastatic Castration-resistant Prostate Cancer (4) Metastatic Prostate Cancer (2) Prostatic Neoplasms, Castration-Resistant (2) Localized Prostate Cancer (1) Prostatic Neoplasms (1) Prostate Neoplasms (1) Oligometastatic Prostate Cancer (1) Metastatic Castration-resistant Prostate Cancer, mCRPC (1) mCRPC (1) Metastatic Castration-Resistant Prostate Cancer Patients (1) Castration-resistant Prostate Cancer (1)
small molecule (26), mixed (3), other (1)
Peter MacCallum Cancer Centre, Australia (2) Weill Medical College of Cornell University (2) Clarity Pharmaceuticals (2) C Ray Therapeutics (2) National Cancer Institute (NCI) (1) Chunjing Yu (1) Nova Therapeutics (1) Jinming Zhang (1) Eli Lilly (1) Xiaorong Sun (1) University Hospital, Basel, Switzerland (1) Fusion Pharmaceuticals (1) Lantheus Medical Imaging (1) M.D. Anderson Cancer Center (1) Columbia University (1) Sinotau Pharmaceutical Group (1) Norroy Bioscience (1) Inovio Pharmaceuticals (1) Curium US (1) First Affiliated Hospital of Fujian Medical University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.